+

WO1992006696A1 - Procede d'obtention d'une preparation bioactive a partir du sang - Google Patents

Procede d'obtention d'une preparation bioactive a partir du sang Download PDF

Info

Publication number
WO1992006696A1
WO1992006696A1 PCT/SU1991/000082 SU9100082W WO9206696A1 WO 1992006696 A1 WO1992006696 A1 WO 1992006696A1 SU 9100082 W SU9100082 W SU 9100082W WO 9206696 A1 WO9206696 A1 WO 9206696A1
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
subject
product
blood
weight
Prior art date
Application number
PCT/SU1991/000082
Other languages
English (en)
Russian (ru)
Inventor
Evgeny Anatolievich Khalaim
Vladimir Nikolaevich Kolosjuk
Sergei Nikolaevich Storozhuk
Stepan Stepanovich Semotjuk
Leonty Ivanovich Sandulyak
Original Assignee
Innovatsionno-Venchurnaya Firma 'chernovitsky Gorodskoi Tsentr Nauchno-Tekhnicheskogo Tvorchestva Molodezhi 'ort'
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovatsionno-Venchurnaya Firma 'chernovitsky Gorodskoi Tsentr Nauchno-Tekhnicheskogo Tvorchestva Molodezhi 'ort' filed Critical Innovatsionno-Venchurnaya Firma 'chernovitsky Gorodskoi Tsentr Nauchno-Tekhnicheskogo Tvorchestva Molodezhi 'ort'
Publication of WO1992006696A1 publication Critical patent/WO1992006696A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays

Definitions

  • the preceding level of technology is a well-known use of irradiated ultra-violet rays for the purpose of treatment and treatment of various diseases.
  • the method of ultimately irradiating the core (vv, v, 1042758) is known, which is omitted if mixed with it and is better observed. When taken from a vein, after irradiation, it returns to a vein, causing a whole range of positive biases in the patient’s organism.
  • the method is used in the treatment of heart-related diseases, toxic and vascular diseases and other diseases.
  • the 0.8–0.9-percent water supply is suitable for refrigerated or buffered refrigerant 7.
  • the target product may be obtained both in liquid and in dry form. In order to receive the target product in its purest form, they carry out the freezing of the supernatant.
  • the resulting mixture is ultimately dispensed with, preferably with an irradiation of 45,000-55,000 J / m.
  • the resulting mixture is centrifuged, If necessary, pressurized liquid can be dried dry.
  • ⁇ e ⁇ s ⁇ e ⁇ imen ⁇ e is ⁇ lz ⁇ valis two g ⁇ u ⁇ y ⁇ l ⁇ v ⁇ z- ⁇ ely ⁇ Instituts ⁇ v white ⁇ ⁇ ys: ⁇ y ⁇ naya (10 zhiv ⁇ ny ⁇ s ⁇ s ⁇ ednim 30 ves ⁇ m early ⁇ y ⁇ a 133.8 g) and ⁇ n ⁇ lnaya (10 zhiv ⁇ ny ⁇ s ⁇ s ⁇ ednim ves ⁇ m early ⁇ y ⁇ a 140.8 g). Livestock was kept under standard conditions (temperature 20-22 ° ⁇ , humidity 40-60), had the possibility of free-standing
  • Example 2 20 ° C is stored at a temperature of 4 ° C until I year. When using the product, it is dissolved in distilled water and introduced into the body from the calculation of 60 mg / kg of live weight. Example 2. The process is analogous to that described in Example I.
  • the raw materials used are stored, obtained from live animals, and stabilized with a unit of 25 units / ml. Separate peripheral elements are washed out with a buffer solution for the process-7.2, then they are mixed with a buffer system-7.2 at a ratio of 1: 2.0.
  • the resulting suspension is ultraviolet irradiated at a dose of 45,000 J / m 2 . Then, the irradiated mixture is centrifuged, separates the hardened liquid and freezes it.
  • Example II The biological product of Example I was tested in animals for weight gain in a young child’s body weight. - 6
  • the biological product was distributed in 350 ml of distilled water and the young man was introduced from the calculation of 60 mg per I kg of live weight.
  • the drug was administered 2 times with an interval of 100 days.
  • the effective period of the drug is 15 days from the last injection.
  • the results of the operation of the appliance were equal to the results obtained from the young team, which introduced a 0.9% external product. The results obtained are given in table I.
  • the increase in the average weight gain in live weight compared to the experimental one is ⁇ 6 kg.
  • Example 15 Biologically active product of Example 2 was tested in tests of weight gain of products.
  • the drug was diluted in distilled water and administered in a dose of 60 mg / kg live weight.
  • the on-line team introduced 0.9 ⁇ -th aqueous solution on the
  • Deliberate applicability of the presently claimed method of biologically active treatment is used in animal husbandry to increase the weight of animals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procédé d'obtention d'une préparation bioactive à partir du sang consistant à extraire du sang des éléments formés et à les mélanger à une solution isoosmotique, le mélange obtenu étant soumis à un rayonnement ultraviolet, de préférence dosé entre 45 000 et 55 000 J/m2, ce qui entraîne une séparation du liquide surnageant et permet d'obtenir le produit désiré.
PCT/SU1991/000082 1990-10-11 1991-05-06 Procede d'obtention d'une preparation bioactive a partir du sang WO1992006696A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SU4872357/14 1990-10-11
SU4872357 1990-10-11

Publications (1)

Publication Number Publication Date
WO1992006696A1 true WO1992006696A1 (fr) 1992-04-30

Family

ID=21539498

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SU1991/000082 WO1992006696A1 (fr) 1990-10-11 1991-05-06 Procede d'obtention d'une preparation bioactive a partir du sang

Country Status (1)

Country Link
WO (1) WO1992006696A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064228A1 (fr) * 2000-02-29 2001-09-07 Owen Holding Ltd Procede de production d'une substance biologiquement active a partir du serum sanguin
US6986867B2 (en) 1999-06-03 2006-01-17 Baxter International Inc. Apparatus, systems and methods for processing and treating a biological fluid with light
US7068361B2 (en) 1999-06-03 2006-06-27 Baxter International Apparatus, systems and methods for processing and treating a biological fluid with light
RU2302237C2 (ru) * 2003-12-26 2007-07-10 Шестаков Виталий Александрович Способ получения биологически активной фракции s-1-10, фармацевтическая композиция, снижающая тремор при паркинсонизме и судорожную активность при эпилепсии

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136161A (en) * 1976-03-16 1979-01-23 Ortho Diagnostics, Inc. Stabilized erythrocytes and methods therefor
EP0106309A2 (fr) * 1982-10-12 1984-04-25 Kailash Kumar Dr. Prof. Gauri Extraits biologiquement actifs, procédé pour leur obtention, agents pharmaceutiques et cosmétiques les contenant et leur utilisation comme additifs pour des produits alimentaires et stimulants
US4618494A (en) * 1984-07-20 1986-10-21 Immunology Development Corporation Human Immune Factors and processes for their production and use
WO1988001510A1 (fr) * 1986-08-26 1988-03-10 Baxter Travenol Laboratories, Inc. Irradiation de produits sanguins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136161A (en) * 1976-03-16 1979-01-23 Ortho Diagnostics, Inc. Stabilized erythrocytes and methods therefor
EP0106309A2 (fr) * 1982-10-12 1984-04-25 Kailash Kumar Dr. Prof. Gauri Extraits biologiquement actifs, procédé pour leur obtention, agents pharmaceutiques et cosmétiques les contenant et leur utilisation comme additifs pour des produits alimentaires et stimulants
US4618494A (en) * 1984-07-20 1986-10-21 Immunology Development Corporation Human Immune Factors and processes for their production and use
WO1988001510A1 (fr) * 1986-08-26 1988-03-10 Baxter Travenol Laboratories, Inc. Irradiation de produits sanguins

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6986867B2 (en) 1999-06-03 2006-01-17 Baxter International Inc. Apparatus, systems and methods for processing and treating a biological fluid with light
US7068361B2 (en) 1999-06-03 2006-06-27 Baxter International Apparatus, systems and methods for processing and treating a biological fluid with light
US7459695B2 (en) 1999-06-03 2008-12-02 Fenwal, Inc. Apparatus, and systems for processing and treating a biological fluid with light
US7601298B2 (en) 1999-06-03 2009-10-13 Fenwal, Inc. Method for processing and treating a biological fluid with light
WO2001064228A1 (fr) * 2000-02-29 2001-09-07 Owen Holding Ltd Procede de production d'une substance biologiquement active a partir du serum sanguin
RU2236238C2 (ru) * 2000-02-29 2004-09-20 Шестаков Виталий Александрович Способ получения биологически активной субстанции из сыворотки крови
RU2302237C2 (ru) * 2003-12-26 2007-07-10 Шестаков Виталий Александрович Способ получения биологически активной фракции s-1-10, фармацевтическая композиция, снижающая тремор при паркинсонизме и судорожную активность при эпилепсии

Similar Documents

Publication Publication Date Title
WO1995003074A1 (fr) Preparation d''ostim apatite' stimulant la croissance des tissus osseux
EP0617958A4 (fr) Composition pharmaceutique presentant des actions anti-alcool stimulant le metabolisme de l'energie, stimulant les fonctions de production et de secretion d'acide de la membrane muqueuse de l'estomac, et presentant egalement des actions radioprotectr
WO1990012584A1 (fr) Preparation ayant un action anti-inflammatoire, lactogene et stimulante, et procede pour sa fabrication
WO1990013305A1 (fr) Preparation pharmaceutique de traitement de la mastite chez l'animal et chez l'homme
EA000885B1 (ru) Лекарственное средство и способ медикаментозного воздействия на организм
WO1995022336A1 (fr) Agent immunomodulateur et reducteur du dysfonctionnement du systeme de regulation de la propagation de cellules tissulaires
WO2001064228A1 (fr) Procede de production d'une substance biologiquement active a partir du serum sanguin
WO1995011659A2 (fr) Preparation pharmaceutique a proprietes immunocorrectrices basee sur une suspension cellulaire et procede de traitement du diabete sucre base sur son utilisation
WO1992006696A1 (fr) Procede d'obtention d'une preparation bioactive a partir du sang
EP0348507A4 (en) Pharmaceutical preparation for individual prophylaxis of venereal diseases and curing urogenital trichomoniasis
AU608545B2 (en) An improved method
WO2000053626A1 (fr) Peptide ayant une activite antitumorale, protectrice et de normalisation, et composition pharmaceutique
RU2686073C1 (ru) Способ получения порошка тканевого препарата растительного происхождения
RU2083209C1 (ru) Способ профилактики и лечения желудочно-кишечных болезней телят
WO1991000098A1 (fr) Preparation anti-inflammatoire et son procede d'obtention
EP1369122A4 (fr) Agent anticancereux
WO2004064849A1 (fr) Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale
RU2254856C1 (ru) Способ профилактики и лечения заболеваний животных
WO1995008318A2 (fr) Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse
Tiegs THE FUNCTION OF CREATINE IN MUSCULAR CONTRACTION.
WO1999015185A1 (fr) Agent permettant de modifier la proliferation, l'activite fonctionnelle et la mort de cellules normales et cancereuses
RU2053767C1 (ru) Комплексный терапевтический препарат для ветеринарии "биофеном"
WO1997045530A1 (fr) Utilisation de souches de streptococcus faecium et composition a base de ces souches
RU2827855C1 (ru) Инъекционное средство для снижения заболеваемости и повышения продуктивности телят
WO2000067766A1 (fr) Preparation reparatrice et regeneratrice, procede de fabrication et utilisation therapeutique selon l.v. doubinina

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载